What we do Vista Pharmaceuticals Ltd formulates and markets pharmaceutical products focusing on gastrointestinal, pain management and anti-infection therapies, serving prescription and OTC markets primarily in India and globally. |
Founded in 1,991 |
Market share Pioneer Indian company with USFDA approvals; significant contributor to domestic and US markets for OTC and generic drugs. |
Problem solved Providing affordable, high-quality pharmaceutical formulations addressing common ailments like infections, pain, and gastrointestinal disorders. |
Top clients or who we serve B2B and B2C sectors including hospitals, pharmacies, and healthcare providers in India and the US markets. |
Key management Dr. Dhananjaya Alli (Chairman & Whole Time Director), Mr. Murali Meraga (Managing Director), Mr. Pavan Sathvik Gilaka (Whole Time Director). |
Our journey and innovations First Indian company to receive USFDA approval for OTC and prescription drugs (1994), expanded ANDA manufacturing facility with USFDA standards in India. |
Where we operate Primarily India and United States with a global marketing and distribution network. |
Top products or what we offer Tablets, capsules, liquids covering gastrointestinal, pain management, and anti-infection therapeutic categories. |
Top brands - |
Raw materials needed Active pharmaceutical ingredients (APIs), excipients for drug formulation. |
Raw materials supplier Not specified; sourced according to compliance and quality standards. |
Recurring vs cyclical contribution Revenue mainly from cyclical pharmaceutical sales with potential recurring orders from distribution networks. |
Our industry position Established player with USFDA-approved manufacturing facilities; competitive in generic and OTC pharmaceutical sectors. |
Financial highlights FY 2024-25 revenue of Rs. 10.07 Cr; loss of Rs. 4.65 Cr; ongoing investments for expansion and regulatory compliance. |
Geographical revenue split Revenue primarily from Indian market and US exports; no detailed split provided. |
Order book - |
Whats driving growth Expansion of manufacturing capacity, USFDA approvals, increasing demand in generic and OTC pharmaceutical segments. |
Our future plans Scaling production capacity with a 100% EOU plant; focus on innovation and global market expansion. |
Our green promise Committed to energy-efficient operations and green initiatives including digital communication to reduce paper use. |
Our people and values Emphasizes employee development, maintains harmonious industrial relations, fosters ethical and transparent governance. |
Key challenges ahead Competitive pharmaceutical market, regulatory compliance costs, and achieving profitability. |
Interesting facts First Indian company to export OTC and prescription drugs to the US market in 1996. |
Risks and strategy Risks from regulatory changes and market competition mitigated through cGMP compliance and quality focus. |
